Prospective studies are needed to define the optimal duration of preoperative therapy, the timing of surgery, and the role of maintenance ALK-TKI therapy after surgery to further improve outcomes for locally advanced ALK fusion gene–positive NSCLC patients. The gene discussed is ALK; the disease is non-small cell lung carcinoma.